Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Liabilities: 2019-2025

Historic Total Liabilities for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $155.8 million.

  • Kymera Therapeutics' Total Liabilities rose 9.78% to $155.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.8 million, marking a year-over-year increase of 9.78%. This contributed to the annual value of $142.4 million for FY2024, which is 21.22% down from last year.
  • Kymera Therapeutics' Total Liabilities amounted to $155.8 million in Q3 2025, which was down 2.38% from $159.6 million recorded in Q2 2025.
  • Kymera Therapeutics' Total Liabilities' 5-year high stood at $189.3 million during Q1 2021, with a 5-year trough of $113.0 million in Q4 2022.
  • In the last 3 years, Kymera Therapeutics' Total Liabilities had a median value of $151.9 million in 2023 and averaged $151.5 million.
  • Per our database at Business Quant, Kymera Therapeutics' Total Liabilities surged by 101.81% in 2021 and then fell by 29.04% in 2022.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Total Liabilities stood at $146.3 million in 2021, then decreased by 22.76% to $113.0 million in 2022, then surged by 60.01% to $180.8 million in 2023, then declined by 21.22% to $142.4 million in 2024, then increased by 9.78% to $155.8 million in 2025.
  • Its last three reported values are $155.8 million in Q3 2025, $159.6 million for Q2 2025, and $132.1 million during Q1 2025.